Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

Fig. 2Fig. 2

a Cumulative total mortality (IPTW) after starting treatment with a GLP-1RA or a SGLT-2i. b Cumulative incidence rates of MACE (IPTW) after starting treatment with a GLP-1RA or a SGLT-2i. HRs SGLT-2 inhibitor vs. GLP-1 receptor agonist 1.03 (0.89–1.21). c Cumulative incidence stroke (IPTW) after starting treatment with a GLP-1RA or a SGLT-2i. HRs SGLT-2 inhibitor vs. GLP-1 receptor agonist 1.44 (0.99–2.08). d Cumulative incidence rates of retinopathy (IPTW) after starting treatment with a GLP-1RA or a SGLT-2i. HRs SGLT-2 inhibitor vs. GLP-1 receptor agonist 2.15 (0.92–5.03). e Cumulative incidence rates of peripheral artery disease (IPTW) after starting treatment with a GLP-1RA or a SGLT-2i. HRs SGLT-2 inhibitor vs. GLP-1 receptor agonist 1.68 (1.04–2.72). f Cumulative incidence rates of congestive heart failure (IPTW) after starting treatment with a GLP-1RA or a SGLT-2i. HRs SGLT-2 inhibitor vs. GLP-1 receptor agonist 0.83 (0.65–1.07)

Back to article page